Scientists describe the role of a p53 target gene in lymphoma and lung cancer development

November 27, 2020

Anew study from the UPF and WEHI (the Walter and Eliza Hall Institute of Medical Research) in Melbourne, Australia, has described the role of p53 target gene Zmat3 in lymphoma and lung cancer development. The study, conducted in pre-clinical mice models, has been led by Ana Janic, laboratory head of the Cancer Biology group at UPF and Kate Sutherland, laboratory head in the Cancer Biology and Stem Cells Division at WEHI. The findings have been published in the journal Cell Death & Disease.

The gene p53 is known as the "guardian of the genome" due to its role in protecting cells from cancer by repairing DNA or by killing cells if they have irreparable damage. More than half the cancers in the world involve mutations in the p53 gene, but how it performs its role remains poorly understood. Importantly, p53 works in combination with other genes, and thus the characterisation of its target genes is essential to contribute to the cancer battle.

Zmat3, one of the p53 target genes, was identified more than 10 years ago and it has been shown to be altered in human cancers. The purpose of this research was to examine whether this protein could have critical functions that p53 uses to prevent cancer. To answer this question, the researchers eliminated Zmat3 to disable the p53-Zmat3 pathway in pre-clinical mice models of lymphomas and lung cancer in which p53 is known to have critical function.

Ana Janic explains that, to their surprise: "we found that removing ZMAT3 had little impact on the tumor development or severity of malignant disease. Our findings have shifted the focus of how Zmat3 could function in tumor development". She adds that "it is likely that at least in some types of blood and lung cancers, it is not Zmat3 protein alone but several proteins that work together to prevent cancer formation". Further research to identify these proteins and how their functions are integrated will be an important step towards understanding the tumour-suppressing function of p53. "Ultimately, this knowledge will have therapeutic impact on the identification of novel strategies to restore p53 function in tumors." Ana Janic concludes.
-end-


Universitat Pompeu Fabra - Barcelona

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.